NPPA fixes retail price of Sun pharma's Amoxycillin, Potassium Clavulanate Oral Suspension
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed the retail price of antibiotic fixed dose combination drug, Amoxycillin and Potassium Clavulanate Oral Suspension IP, manufactured and marketed by Sun Pharmaceutical at Rs 168.43 Per Vial (50ml).This price fixation came in accordance...
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed the retail price of antibiotic fixed dose combination drug, Amoxycillin and Potassium Clavulanate Oral Suspension IP, manufactured and marketed by Sun Pharmaceutical at Rs 168.43 Per Vial (50ml).
This price fixation came in accordance with the decision of 104th Authority meeting dated 23rd November where the new drug applications for price fixation under para 5 and para 15 of DPCO 2013 were discussed.
During the meeting, the authority suggested the retail price of each vial (50 ml) of antibiotic fixed dose combination drug, Amoxycillin and Potassium Clavulanate Oral Suspension IP manufactured and marketed by Sun Pharmaceutical will be 168.43 Per Vial (50ml).
Each 5 ml of the reconstituted suspension contains Amoxicillin trihydrate IP, equivalent to Amoxicillin 600 mg and Potassium Clavulanate diluted IP equivalent to Clavulanic acid 42.09 mg.
Amoxicillin is a penicillin derivative used for the treatment of infections caused by gram-positive bacteria, in particular streptococcal bacteria causing upper respiratory tract infections.
Amoxicillin competitively inhibits penicillin-binding protein and other high molecular weight penicillin binding proteins. Penicillin bind proteins are responsible for glycosyltransferase and transpeptidase reactions that lead to cross-linking of D-alanine and D-aspartic acid in bacterial cell walls. Without the action of penicillin binding proteins, bacteria upregulate autolytic enzymes and are unable to build and repair the cell wall, leading to bacteriocidal action.
Clavulanic acid is a beta-lactamase inhibitor that is frequently combined with Amoxicillin or Ticarcillin to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening their spectrum of susceptible bacterial infections. Clavulanic acid is derived from the organism Streptomyces clavuligerus.
In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), has fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Name of the Formulation / Brand Name
Manufacturer & Marketing Company
Retail Price (Rs.)
Amoxycillin and Potassium Clavulanate Oral Suspension IP
Each 5ml of the reconstituted suspension contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 600mg Potassium Clavulanate diluted IP eq. to Clavulanic Acid 42.09mg
Per Vial (50ml)
M/s Sun Pharmaceutical Industries Limited
The notice further added,
(a) The manufacturer of above-mentioned formulations i.e., "new drug" under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
Susmita Roy, Bpharm, Mpharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in pharmacy. She holds a master ’s degree in pharmacology. She is currently employed at Haldia Institute of Pharmacy as an assistant professor. She has been a part of Medical Dialogue since March 2021. She can be contacted at email@example.com